NIH begins clinical trial of hydroxychloroquine and azithromycin to treat COVID-19

A clinical trial has begun to evaluate whether the malaria drug hydroxychloroquine, given together with the antibiotic azithromycin, can prevent hospitalization and death from coronavirus disease 2019 (COVID-19). The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, is sponsoring the trial, which is being conducted by the NIAID-funded…

Details

ACTG launches clinical trial testing treatment for COVID-19

Los Angeles, Calif. – The AIDS Clinical Trials Group (ACTG), the world’s largest and longest established HIV research network, today announced the initiation of ACTG 5395, a clinical trial to evaluate whether the drug combination hydroxychloroquine and azithromycin can prevent hospitalization and death from COVID-19 (which is caused by infection with the virus SARS-CoV-2). There…

Details

Online exercise advice rarely aligns with national physical activity guidelines

CORVALLIS, Ore. — Whether for convenience, cost or comfort, many people look to online resources for fitness and exercise information — especially when faced with fitness center and gym closures during the COVID-19 pandemic. Unfortunately, most internet-based recommendations for physical activity don’t match up with the guidelines supported by national health organizations, a recent study…

Details

BioCompute Object Specification Project receives IEEE Standardization Acceptance

WASHINGTON (May 14, 2020) – The BioCompute Object Specification Project led by a team at the George Washington University has been officially approved for publication as an internationally recognized standard by the Institute of Electrical and Electronics Engineers (IEEE) Standards Association. Standardization will open the door to government agencies and large institutions formalizing the process…

Details

SCAI issues device selection guidelines for aorto-iliac arterial interventions

WASHINGTON – The Society for Cardiovascular Angiography and Interventions (SCAI) has released guidelines that provide a comprehensive review of comparative effectiveness data for devices used in aorto-iliac arterial interventions. The recommendations aim to provide clinicians with guidance for device selection in patients for whom these devices are intended as definitive therapy. The document was published…

Details

SCAI releases official position statement on optimal percutaneous interventional therapy for complex coronary artery disease

WASHINGTON – The Society for Cardiovascular Angiography and Interventions (SCAI) has published a position statement addressing optimal percutaneous coronary intervention (PCI) treatment of patients with complex coronary artery disease (CAD). The position statement was presented today during the SCAI 2020 Scientific Sessions Virtual Conference and published in SCAI’s official journal, Catheterization and Cardiovascular Interventions. While…

Details